The Top 5 Analyst Questions From Pfizer's Q2 Earnings Call

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance to a robust showing across its commercial portfolio, especially in oncology, vaccines, and rare disease products. CEO Albert Bourla highlighted that disciplined cost control and productivity enhancements—including expanded use of automation and AI—contributed to improved operating margins. The company also benefited from higher-than-anticipated demand for several newly launched products and continued international momentum, particularly for its Vyndaqel family and key oncology brands.

Is now the time to buy PFE? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call

• Trung Chuong Huynh (UBS) pressed for details on the impact of government policy changes on guidance. CEO Albert Bourla noted active discussions with policymakers but declined to provide specific figures, citing ongoing negotiations.
• Chris Schott (JPMorgan) asked about Pfizer’s business development strategy and new leverage target. CFO David Denton explained the shift toward smaller transactions, enabled by improved cash generation and a new 2.7x leverage target.
• Alex Hammond (Wolfe Research) questioned the scalability of the direct-to-consumer purchase model for Eliquis. Bourla confirmed plans to expand similar initiatives to other products, emphasizing collaboration with industry peers and policymakers.
• Mohit Bansal (Wells Fargo) sought clarification on why revenue guidance was not raised further despite a strong quarter. Denton explained the company was “de-risking” guidance for potential volatility in COVID revenues in the second half.
• Courtney Breen (Bernstein) inquired about SG&A efficiencies and capital allocation priorities. Commercial leaders detailed targeted investment in growth products and markets, while Bourla reiterated focus on oncology, obesity, and immunology for future M&A.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be tracking (1) Phase III readouts for Padcev and Elrexfio, which could drive label expansions and incremental revenue, (2) the pace and impact of cost-saving initiatives on operating margins, and (3) resolution of U.S. policy negotiations around drug pricing and tariffs. The contribution of recently acquired and launched products will also be a critical marker of execution.

Pfizer currently trades at $24.63, up from $23.54 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.